Mechanism analysis of probiotics in delaying the progression of early Alzheimer's disease
10.3969/j.issn.1673-9701.2025.21.005
- VernacularTitle:益生菌延缓早期阿尔茨海默病病情加重的机制分析
- Author:
Danping LYU
1
;
Xiuqin LIN
1
;
Xinyuan ZHANG
1
;
Lili GUAN
1
;
Qundi SHEN
1
Author Information
1. 绍兴市第七人民医院检验科,浙江绍兴 312000
- Publication Type:Journal Article
- Keywords:
Early Alzheimer's disease;
Probiotics;
Brain-gut-microbiota axis;
Gut microbiota;
Inflammation of the nervous system
- From:
China Modern Doctor
2025;63(21):18-22
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the feasibility of probiotics in delaying the progression of early Alzheimer's disease(AD)based on the changes of brain-gut-microbiota axis factors.Methods A total of 100 patients with early AD who visited Shaoxing 7th People's Hospital from December 2023 to December 2024 were selected and divided into control group(40 cases)and study group(60 cases)based on different treatment methods.The control group was treated with donepezil hydrochloride,while study group was treated with donepezil hydrochloride combined with probiotic preparations.The cognitive function,daily living ability,intestinal flora,and relative expression levels of brain-gut-microbiota axis factors,interleukin(IL)-6,tumor necrosis factor-α(TNF-α),5-hydroxytryptamine(5-HT),γ-aminobutyric acid(GABA),and lipopolysaccharide(LPS)/Toll-like receptor 4(TLR4)/nuclear factor-KB(NF-κB)axis factors were compared before and after treatment in both groups.The clinical efficacy and prognosis monitoring results were also compared.Results The total effective rate and the proportion of patients with a clinical dementia rating score of 0 in study group were higher than those in control group(P＜0.05).The cognitive function and daily living ability scores in study group were higher than those in control group(P＜0.05).The copy numbers of lactobacillus and bifidobacterium in study group were higher than those in control group,while the copy numbers of enterococcus and escherichia coli were lower(P＜0.05).The relative expression levels of amyloid-β protein 1-42,IL-6,TNF-α,TLR4,and NF-κB in study group were lower than those in control group,and the levels of 5-HT and GABA were higher(P＜0.05).Conclusion Probiotics can delay the progression of early AD patients and improve clinical efficacy.It is speculated that the mechanism of action may be related to regulating the brain-gut-microbiota axis-mediated LPS/TLR4/NF-κB pathway to restore the intestinal microecology and alleviate neurological inflammation.
